Last reviewed · How we verify
Triamcinolone + Betamethason
Triamcinolone and betamethasone are synthetic glucocorticoids that inhibit the release of inflammatory mediators.
Triamcinolone and betamethasone are synthetic glucocorticoids that inhibit the release of inflammatory mediators. Used for Severe asthma attacks, Severe allergic reactions (anaphylaxis), Severe skin conditions (e.g. psoriasis, eczema).
At a glance
| Generic name | Triamcinolone + Betamethason |
|---|---|
| Also known as | Injectable Steroid |
| Sponsor | Iran University of Medical Sciences |
| Drug class | Glucocorticoid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
They work by binding to glucocorticoid receptors, which then translocate to the nucleus and inhibit the transcription of pro-inflammatory genes. This leads to a decrease in the production of inflammatory cytokines and other mediators, resulting in anti-inflammatory and immunosuppressive effects.
Approved indications
- Severe asthma attacks
- Severe allergic reactions (anaphylaxis)
- Severe skin conditions (e.g. psoriasis, eczema)
- Severe inflammatory conditions (e.g. rheumatoid arthritis, lupus)
Common side effects
- Cushing's syndrome
- Glucocorticoid-induced osteoporosis
- Increased risk of infections
- Hypertension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triamcinolone + Betamethason CI brief — competitive landscape report
- Triamcinolone + Betamethason updates RSS · CI watch RSS
- Iran University of Medical Sciences portfolio CI